Description: Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
Home Page: spagonanomedical.se
ScheelevAegen 22
Lund,
223 63
Sweden
Phone:
46 4 68 11 88
Officers
| Name | Title |
|---|---|
| Dr. Mats Hansen M.Sc., Ph.D. | Chief Executive Officer |
| Ms. Hanna Olsson M.Sc. | Chief Financial Officer |
| Dr. Oskar Axelsson M.Sc., Ph.D. | Head of Research & Chief Scientific Officer |
| Mr. Paul Hargreaves | Chief Development Officer |
| Ms. Birgitta Rembratt Svensson | Head of CMC & Supply |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.304 |
| Price-to-Sales TTM: | 0.7809 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 12 |